[go: up one dir, main page]

MY186929A - Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production - Google Patents

Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production

Info

Publication number
MY186929A
MY186929A MYPI2017701499A MYPI2017701499A MY186929A MY 186929 A MY186929 A MY 186929A MY PI2017701499 A MYPI2017701499 A MY PI2017701499A MY PI2017701499 A MYPI2017701499 A MY PI2017701499A MY 186929 A MY186929 A MY 186929A
Authority
MY
Malaysia
Prior art keywords
methods
production
dimeric immunoglobulins
hetero
cell retargeting
Prior art date
Application number
MYPI2017701499A
Inventor
Ollier Romain
Hou Samuel
Lissilaa Rami
Skegro Darko
Back Jonathan
Original Assignee
Ichnos Sciences SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2014/073738 external-priority patent/WO2015063339A1/en
Application filed by Ichnos Sciences SA filed Critical Ichnos Sciences SA
Publication of MY186929A publication Critical patent/MY186929A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to hetero-dimeric immunoglobulins that target both a component of the human CD3 antigen and a component of the human CD38 antigen and methods of making the same. The present invention also relates to antibodies which bind to the human CD38 antigen and derivatives thereof for use as therapeutic or diagnostic reagents and methods of making the same.
MYPI2017701499A 2014-11-04 2015-11-03 Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production MY186929A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2014/073738 WO2015063339A1 (en) 2013-11-04 2014-11-04 Production of t cell retargeting hetero-dimeric immunoglobulins
EP15167034 2015-05-08
PCT/EP2015/075628 WO2016071355A1 (en) 2014-11-04 2015-11-03 Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production

Publications (1)

Publication Number Publication Date
MY186929A true MY186929A (en) 2021-08-26

Family

ID=53059011

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2017701499A MY186929A (en) 2014-11-04 2015-11-03 Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production

Country Status (19)

Country Link
EP (1) EP3215541A1 (en)
JP (3) JP2018501297A (en)
CN (1) CN107207596A (en)
AU (1) AU2015341884B2 (en)
BR (1) BR112017009263A2 (en)
CA (1) CA2965745C (en)
CL (1) CL2017001090A1 (en)
CO (1) CO2017005240A2 (en)
EA (1) EA039658B1 (en)
HK (1) HK1244014A1 (en)
IL (1) IL251848A0 (en)
MA (1) MA40894A (en)
MX (1) MX2017005814A (en)
MY (1) MY186929A (en)
NZ (1) NZ732019A (en)
PE (1) PE20171041A1 (en)
PH (1) PH12017500819A1 (en)
SG (1) SG11201703313SA (en)
WO (1) WO2016071355A1 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
KR102391731B1 (en) 2013-01-14 2022-04-27 젠코어 인코포레이티드 Novel heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US11161906B2 (en) 2013-07-25 2021-11-02 Cytomx Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
SG10201909806SA (en) 2013-11-04 2019-11-28 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
ES2775431T3 (en) 2014-03-28 2020-07-27 Xencor Inc Bispecific Antibodies Binding to CD38 and CD3
US10669337B2 (en) 2014-07-25 2020-06-02 Cytomx Therapeutics, Inc. Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
WO2016086196A2 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
MA55043A (en) 2014-11-26 2021-12-29 Xencor Inc HETERODIMERIC ANTIGEN-BINDING ANTIGEN CD3 AND CD20 ANTIGEN
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
TWI744242B (en) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Antibody constructs for egfrviii and cd3
TWI796283B (en) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Antibody constructs for msln and cd3
TWI829617B (en) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Antibody constructs for flt3 and cd3
CN108699136B (en) 2015-12-07 2022-03-18 Xencor股份有限公司 Heterodimeric antibodies that bind CD3 and PSMA
EA039859B1 (en) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Bispecific antibody constructs binding egfrviii and cd3
IL263542B2 (en) 2016-06-14 2024-10-01 Xencor Inc Bispecific checkpoint inhibitor antibodies
MX2018016265A (en) 2016-06-28 2019-07-04 Xencor Inc Heterodimeric antibodies that bind somatostatin receptor 2.
CA3060190A1 (en) * 2017-04-24 2018-11-01 Glenmark Pharmaceuticals S.A. T cell redirecting bispecific antibodies for the treatment of egfr positive cancers
WO2018224441A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
CA3064163A1 (en) 2017-06-05 2018-12-13 Numab Therapeutics AG Novel anti-cd3 antibodies
JP2020523038A (en) 2017-06-08 2020-08-06 ブラック ベルト セラピューティクス リミテッド CD38 regulatory antibody
EP3635002A1 (en) * 2017-06-08 2020-04-15 Black Belt Therapeutics Limited Cd38 modulating antibody
ES2911243T3 (en) * 2017-08-10 2022-05-18 Grifols Diagnostic Solutions Inc Compositions, methods and/or kits comprising a recombinant extracellular domain of human cd38
JP7299873B2 (en) 2017-08-16 2023-06-28 ブラック ベルト セラピューティクス リミテッド CD38 antibody
US11542338B2 (en) 2017-08-16 2023-01-03 Black Belt Therapeutics Limited CD38 modulating antibody
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Multispecific molecules that bind to bcma and uses thereof
BR112020007309A2 (en) 2017-10-14 2020-09-29 Cytomx Therapeutics, Inc. antibodies, activable antibodies, bispecific antibodies and bispecific activable antibodies and methods of using them
CA3082383A1 (en) 2017-11-08 2019-05-16 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-pd-1 sequences
WO2019195623A2 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
JP2022502683A (en) * 2018-09-25 2022-01-11 イクノス サイエンシズ エスエー Quantification of antibodies in biological samples
KR102353568B1 (en) 2018-11-14 2022-01-20 주식회사 헬릭스미스 Anti c-Met Antibody or Antigen binding fragment thereof with Improved Stability
JP2022523047A (en) 2019-01-23 2022-04-21 エンセファ CD31 competitors and their use
US20220177582A1 (en) * 2019-03-13 2022-06-09 Ichnos Sciences SA Non-consensus glycosylation of bispecific antibodies
KR20220012313A (en) * 2019-05-23 2022-02-03 벨로스바이오 인코포레이티드 anti-ROR1/anti-CD3 bispecific binding molecule
WO2020250940A1 (en) * 2019-06-11 2020-12-17 小野薬品工業株式会社 Immunosuppression agent
CN110551222B (en) * 2019-08-27 2023-06-06 重庆市畜牧科学院 A novel bifunctional antibody and its application
CN112538114A (en) * 2019-09-20 2021-03-23 上海普铭生物科技有限公司 Anti-human CD38 antibody and application thereof
AU2020359928B2 (en) * 2019-09-30 2025-01-09 Harbour Biomed (Shanghai) Co., Ltd. CD3-targeting antibody, bispecific antibody and use thereof
CN113493519B (en) * 2020-03-19 2022-12-27 浙江道尔生物科技有限公司 Fusion protein with remarkably prolonged half-life for treating ocular angiogenesis diseases
EP4139347A4 (en) * 2020-04-24 2024-06-05 Memorial Sloan Kettering Cancer Center Anti-cd3 antibodies and uses thereof
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
CN115916824A (en) * 2020-06-17 2023-04-04 Y-单克隆抗体制药有限公司 CD38 antibodies for the treatment of human diseases
US11919958B2 (en) 2020-08-19 2024-03-05 Xencor, Inc. Anti-CD28 compositions
KR20230154311A (en) 2021-03-10 2023-11-07 젠코어 인코포레이티드 Heterodimeric antibodies binding to CD3 and GPC3

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008504013A (en) * 2004-02-06 2008-02-14 モルフォシス・アクチェンゲゼルシャフト Anti-CD38 human antibody and use thereof
EP1866338B1 (en) * 2005-03-23 2016-09-21 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
JP5362359B2 (en) * 2005-10-12 2013-12-11 モルフォシス アーゲー Generation and profiling of fully human HuCALGOLD-derived therapeutic antibodies specific for human CD38
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
MY152963A (en) * 2009-06-26 2014-12-15 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
KR102103093B1 (en) * 2009-12-25 2020-04-21 추가이 세이야쿠 가부시키가이샤 Polypeptide modification method for purifying polypeptide multimers
LT2580243T (en) * 2010-06-09 2020-01-27 Genmab A/S ANTIBODIES AGAINST HUMAN CD38
JOP20210044A1 (en) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co Anti-CD38 . antibody
MX358752B (en) * 2011-03-25 2018-08-31 Glenmark Pharmaceuticals Sa Hetero-dimeric immunoglobulins.
CA2886036A1 (en) * 2012-09-25 2014-04-03 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
WO2014068114A1 (en) * 2012-11-05 2014-05-08 Morphosys Ag Radiolabelled antibody and uses thereof
SG10201909806SA (en) * 2013-11-04 2019-11-28 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins

Also Published As

Publication number Publication date
IL251848A0 (en) 2017-06-29
CN107207596A (en) 2017-09-26
CO2017005240A2 (en) 2017-10-31
EA039658B1 (en) 2022-02-22
JP7403505B2 (en) 2023-12-22
JP2021184722A (en) 2021-12-09
HK1244014A1 (en) 2018-07-27
EA201790961A1 (en) 2017-10-31
MA40894A (en) 2017-09-12
CA2965745A1 (en) 2016-05-12
JP2018501297A (en) 2018-01-18
KR20170078831A (en) 2017-07-07
PE20171041A1 (en) 2017-07-19
MX2017005814A (en) 2017-08-02
WO2016071355A1 (en) 2016-05-12
NZ732019A (en) 2022-07-29
AU2015341884A1 (en) 2017-06-08
SG11201703313SA (en) 2017-05-30
PH12017500819A1 (en) 2017-10-02
CL2017001090A1 (en) 2018-01-05
EP3215541A1 (en) 2017-09-13
BR112017009263A2 (en) 2018-01-30
JP2019214582A (en) 2019-12-19
CA2965745C (en) 2023-12-05
AU2015341884B2 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
PH12017500819A1 (en) Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production
MX2022011002A (en) Humanized or chimeric cd3 antibodies.
MX2018012757A (en) Agonistic antibodies that bind human cd40 and uses thereof.
MX2021003704A (en) Heterodimeric antibodies that bind cd3 and tumor antigens.
MX2020004503A (en) Humanized or chimeric cd3 antibodies.
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
EP4223874A3 (en) Human anti-il-33 neutralizing monoclonal antibody
MX2022002364A (en) Anti-pd-l1 antibodies.
MX2018008934A (en) Anti-ror1 antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same.
TN2017000470A1 (en) Heterodimeric antibodies that bind cd3 and tumor antigens.
PH12016501908A1 (en) Bispecific antibodies that bind to cd38 and cd3
EA201890285A1 (en) ANTIBODIES AGAINST PD-1, ACTIVATED ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION
PH12016501366A1 (en) Novel anti-baff antibodies
EA201791485A1 (en) ANTI-CD47-ANTIBODIES AND THEIR APPLICATIONS
MX2016009050A (en) Bi-specific cd3 and cd19 antigen-binding constructs.
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
MX2016016883A (en) Anti-axl antibodies.
PH12017501077A1 (en) Compositions and methods for antibodies targeting bmp6
MX2018003183A (en) Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof.
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
NZ724772A (en) Antibodies against hpa-1a
MX2016014726A (en) Her1 antigen binding proteins binding to the beta-hairpin of her1.
MX2017003014A (en) Humanized anti-alpha v beta 5 antibodies and uses thereof.